24 news items
KRAZATI (adagrasib) Demonstrated Statistically Significant Improvement in Progression-Free Survival in Patients with Pretreated Locally Advanced or Metastatic KRASG12C-Mutated Non-Small Cell Lung Cancer
BMY
1 Jun 24
, as assessed by Blinded Independent Central Review (BICR) compared to docetaxel (HR: 0.58; [95% CI, 0.45-0.76]; P <0.0001). Median PFS was 5.5 months
Bristol-Myers Squibb's Options: A Look at What the Big Money is Thinking
BMY
30 May 24
trading surrounding Bristol-Myers Squibb, we move to examine the company in more detail. This includes an assessment of its current market status
U.S. Food and Drug Administration Approves Bristol Myers Squibb's Breyanzi as a New CAR T Cell Therapy for Relapsed or Refractory Mantle Cell Lymphoma
BMY
30 May 24
to treatment, with 67.6% (95% CI: 55.2-78.5) achieving a complete response (CR). Responses were assessed per the 2014 Lugano classification and required
Bristol Myers Squibb to Present Data at ASCO & EHA from More Than 130 Studies Across 25 Diseases Supporting Expansion into New Indications, Demonstrating Long-Term Survival, and Highlighting Novel Modalities and Research Platforms
BMY
23 May 24
-pulmonary symptoms should be assessed for potential myocarditis. If myocarditis is suspected, withhold dose, promptly initiate high dose steroids
AbbVie Is 'Successfully Positioned To Absorb Humira Biosimilar Erosion': Analyst
ABBV
BMY
17 May 24
to assess antipsychotic treatment efficacy.
“When we compare the two products, we believe emraclidine differentiates by its
33bpjvmzeycmu35azh04xt0pahjlzpwump6v1qtmy5l
BMY
16 May 24
, and 57.2% for static Physician's Global Assessment (sPGA) 0/1 (clear/almost clear), using modified nonresponder imputation (mNRI). The safety profile
do0vblx 6emf1cb
BMY
16 May 24
for Psoriasis Area and Severity Index (PASI) 75 and 90 were 71.7% and 47.5%, respectively, and 57.2% for static Physician's Global Assessment (sPGA) 0/1
bha1ws0gqkf43bzy341anwnw91 8w2ff
BMY
15 May 24
or complete response per Lugano criteria as assessed by an Independent Review Committee (IRC). The complete response (CR) rate was 73.4% (95% CI: 63.3
flubnqym449o8yl6 lj1yjrej209qxjl752
BMY
26 Apr 24
on the current state of the company.
Rating: Delving into assessments, analysts assign qualitative values, from 'Outperform
6w0ijyl0ibfg5vmsbu75jka2at0b185l
BMY
26 Apr 24
of overall survival (OS) and progression-free survival (PFS) as assessed by Blinded Independent Central Review (BICR). With a median follow up
5j4pyfi9tj46
BMY
25 Apr 24
as assessed
xq4qol9q1s8zn hkjkth104zv015offgfgmevv26htgdm9pvjpfo9g
BMY
8 Apr 24
of overall response rate.
The study remains ongoing to assess the additional key secondary endpoint of overall survival.
In 2022
1kqnpeos42dtcoa
BMY
6 Apr 24
meaningful changes in movement disorder scale scores over 52 weeks (Oral Session: New Pharmacological Treatments and Assessments and Poster F74
flkhiyyt7kxd7dwp9j0ly
BMY
2 Apr 24
assessment to understand evolving stakeholder views and ensure its business priorities
ok3t3jzi8gwcw5tncj2r57z 7zn
BMY
ZLAB
1 Apr 24
).
The study remains ongoing to assess the additional key secondary endpoint of overall survival.
Results showed that Krazati
prm0vtfdp71u
BMY
CATX
LNTH
28 Mar 24
feasibility assessments on additional sites.Preliminary results from Cohorts 1 and 2 of the Phase 1/2a trial are expected in the third
jype9ijy533g5a0ymcbj8pm2xcleoctguyl1dgkv7
BMY
25 Mar 24
.
Echocardiogram assessments of LVEF are required prior to and during treatment with CAMZYOS. Initiation of CAMZYOS in patients